Bausch Health Companies Inc. announced on October 28, 2026, that its Board of Directors has authorized a share repurchase program allowing the company to repurchase common shares for a total aggregate purchase price of up to US$50 million.

Key Highlights

  • Program size: The Board authorized repurchases of up to US$50 million in total aggregate purchase price.
  • Primary objective: According to the filing, the program is intended "to manage the potential dilutive impact of future employee equity-based compensation."
  • Timeline: Purchases may commence on November 3, 2026, and the program will terminate no later than November 3, 2027.
  • Share cap: The company will not repurchase more than 5% of the 374,266,716 Common Shares outstanding as of October 23, 2026.
  • Share treatment: All Common Shares acquired under the program will be cancelled.
  • Discretionary nature: The company disclosed it is not obligated to acquire any particular number of shares, and the program may be suspended, modified, or discontinued at any time.

Bausch Health's $50 Million Buyback: Program Terms and Scope

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), headquartered in Laval, QC, disclosed that its Board of Directors has approved a Share Repurchase Program permitting the company to buy back its common shares for up to US$50 million in aggregate. According to the filing, the program's primary stated objective is to manage potential dilution from future employee equity-based compensation awards.

The filing states that purchases may be made in the open market on the New York Stock Exchange and other published markets in the United States, with shares purchased at prevailing market prices at the time of each transaction, subject to a maximum price set by the Board of Directors. The filing also notes that the value of any purchases made in Canadian dollars will depend on the applicable exchange rate at the time of purchase. The program is being conducted in reliance on the exemption set forth in section 4.8(3) of National Instrument 62-104 Take-Over Bids and Issuer Bids.

The company disclosed that the actual number of shares repurchased, along with the timing and price of any repurchases, will depend on market conditions, applicable legal requirements, and other factors. The filing confirms the company will not repurchase more than 5% of the 374,266,716 Common Shares that were outstanding as of October 23, 2026. The filing also notes that the Share Repurchase Program may be suspended, modified, or discontinued at any time, and that all acquired shares will be cancelled. The news release includes forward-looking statements that, according to the filing, are subject to risks and uncertainties described in the company's SEC and Canadian regulatory filings.

What Was Disclosed

Bausch Health's Board authorized a share repurchase program of up to US$50 million, running from November 3, 2026, through no later than November 3, 2027, capped at 5% of shares outstanding as of October 23, 2026, with all repurchased shares to be cancelled.